NexImmune

NexImmune is an early stage biopharmaceutical company developing novel immuno-therapeutics based on the proprietary Artificial IMmune (AIMTM) technology. The AIM technology provides an important advance in the development of immunotherapies for a variety of cancers and other diseases.

The AIM technology has been designed to orchestrate specific immune system responses in a highly controllable and reproducible way independent of the healthiness or abundance of the patient’s natural antigen presenting cell (APC) population. Natural APCs are major players in the body’s immune system as they direct the immune system cells in attacks on specifically targeted antigens and cells. However, under certain disease conditions, natural APCs can be damaged, absent or inactive.

NexImmune headquartered in United States, North America, operates in the Biotechnology, Biopharma, Therapeutics sector. The company focuses on Biotechnology and has secured $6.3B in funding across 72 round(s). With a team of 11-50 employees, NexImmune is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - NexImmune, raised $3.0M. Discover more about their projects, partnerships, and impact on our platform.